Written by a model from the transcript; not yet reviewed.
This episode explores the modern understanding of migraines, featuring Dr. Fred Cohn in conversation with Jonathan Fields. The discussion corrects the long-standing myth that migraines are primarily a vascular condition, explaining instead that they are neuroinflammatory events driven by neuropeptides and cortical spreading depression. The guest details the difference between tension headaches, cluster headaches, and migraines, while breaking down prevalence statistics, the reality of auras in only a fraction of cases, and the multi-phase nature of attacks including prodrome and postdrome phases. Listeners gain a thorough overview of acute versus preventive treatments, spanning legacy medications, newer CGRP inhibitors, Botox, lifestyle factors, and emerging therapies like neuromodulation and psychedelics. This conversation offers specific guidance for anyone struggling with chronic head pain, emphasizing that medical approaches have advanced significantly.
The host introduces the episode, explains the long-held vascular theory of migraine, and sets the stage for debunking it.
Dr. Cohn delves into the trigeminal vascular system, CGRP release, and cortical spreading depression as key mechanisms behind migraine pain.
The conversation covers how to differentiate tension, cluster, and migraine headaches, including duration, quality, and when to seek imaging.
Statistical data on migraine prevalence, the higher incidence in women, and the misconception that most migraines involve aura are discussed.
An explanation of what constitutes medication overuse headache, how it develops, and how to prevent rebound headaches.
A chronological overview of preventive medications, including beta‑blockers, anticonvulsants, CGRP monoclonals, and Botox, and how they are chosen for patients.
Discussion of newer options such as neuromodulation devices, ketamine, and GLP‑1 agonists, and their potential mechanisms in migraine management.
The host and doctor review first‑line acute therapies, comparing tryptans and GPANs, their mechanisms, onset times, and routes of administration.
Discussion of how lifestyle factors and medical treatments intersect in migraine management.
Explanation of the importance of sleep stages and the glymphatic system in clearing neuropeptides to reduce migraine.
Review of common migraine triggers, including weather changes, and the role of acute medications during unavoidable triggers.
Overview of ketamine’s role and emerging psychedelic treatments for migraine and cluster headaches.
Migraine is Neuroinflammatory, Not Vascularinsight
The guest explains that the traditional medical teaching of migraines as a blood vessel problem is a myth. Instead, migraines are complex neuroinflammatory conditions driven by the release of inflammatory neuropeptides.
The Trigeminal Vascular System and Switchinsight
A discussion on the mechanical start of a migraine, involving the trigeminal vascular system and a cortical spreading depression wave of potassium release in the brain.
Cluster Headaches and Extreme Paindata
Cluster headaches are distinguished by sudden, incredibly severe, one-sided pain behind the eye lasting 15 minutes to three hours, earning them the historical nickname of suicide headaches.
Epidemiology and Gender Prevalencedata
Migraines affect roughly 40 to 60 million Americans, or about one in six, with a significantly higher prevalence in women at 18% compared to 6% in men, largely influenced by estrogen fluctuations.
Most People Do Not Get Aurainsight
Contrary to popular belief, only about 30 percent of people who experience migraines ever get an aura, which can present as neurological symptoms ranging from visual disturbances to numbness or speech difficulties.
Botox as Chronic Migraine Treatmentstrategy
Botox is FDA-approved specifically for chronic migraine, utilizing 155 to 200 units injected across 31 to 40 sites on the head and neck every three months to interfere with neuropeptide release.
GLP-1 Agonists and Headachesdebate
Recent clinical observations indicate that weight loss medications like Ozempic reduce headache frequency, raising questions about whether the benefit stems directly from reduced inflammation or weight loss.
“Sure. So migraine, you know, our epidemiology, um, suggests it affects anywhere from 40, 60 million Americans.”
“I think the best indicator for the impact of someone's migraine or headache is asking about their function.”
“And it almost becomes normalized where it actually really does become hard to understand.”
“31 to 40 injections are on the head.”
“Sleep is probably the most important thing.”
“You know, there's a lot of safety data, like I'm always reading about.”
“Pain is a concept, if you will, a creation of the brain.”
“If you're a primary doctor, you know, make sure you're making the case that how it's affecting you.”
For decades, migraine was explained to patients as a blood vessel problem: swelling, throbbing, treat it by shrinking things back down. That explanation is mostly a myth, and it may be part of why so many older treatments never worked. Dr. Fred Cohen is medical director of Headache Intervention and an assistant professor of medicine and neurology at the Icahn School of Medicine at Mount Sinai. He's one of the few headache specialists in the country trained in both internal medicine and headache medicine, has over 40 publications in journals including The Lancet and Cephalalgia, and has lived with migraine himself since his teens. In this conversation, you'll explore: Why migraine is a neuroinflammatory condition, not a vascular one, and why some medical schools still teach the outdated versionThe "broken thermostat" phenomenon of chronic sensitization, and how untreated migraine can convince your brain that constant pain is normalWhy only about 30% of people with migraine ever experience aura, and the surprising range of ways it can actually show upThe current treatment landscape, from triptans to CGRP therapies, Botox, neuromodulation devices, and what's coming nextWhy Dr. Cohen calls this the golden age of headache medicine, and what that means if you gave up on treatment years ago If migraine has ever made you feel like your body was working against you, or like you'd already tried everything, this conversation will change how you see both. You can find Fred at: Website https://www.headache123.com/ | Instagram https://www.instagram.com/fredcohenmd/ | Episode Transcript https://www.goodlifeproject.com/podcast/migraine-neuroinflammation-cgrp-fred-cohen Next week, we're sitting down with Marisa Renee Lee to talk about why the tidy stories we tell ourselves about grief and resilience tend to fall apart, and what it actually looks like to build a life around pain instead of waiting to get past it. Be sure to follow Good Life Project wherever you get your podcasts so you don’t miss any upcoming episodes! Check out our sponsors and resources: Visit Our Sponsor Page https://www.goodlifeproject.com/sponsors/ Share your midlife reinvention story with us HERE https://stephanie197.typeform.com/to/BOdLYgvb. Hosted on Acast. See acast.com/privacy https://acast.com/privacy for more information.
12,841 words · 8 speakers
Speaker names marked are inferred from speaking time and the show’s known hosts — they are not voice-verified.
Page updated · transcript and summary are machine-generated